Abstract:AML is a malignant disease of hematopoietic progenitor cells with unsatisfactory treatment outcome, especially in patients that are ineligible for intensive chemotherapy. Immunotherapy, comprising checkpoint inhibition, T-cell engaging antibody constructs, and cellular therapies, has dramatically improved the outcome of patients with solid tumors and lymphatic neoplasms. In AML, these approaches have been far less successful. Discussed reasons are the relatively low mutational burden of AML blasts and the difficulty in defining AML-specific antigens not expressed on hematopoietic progenitor cells. On the other hand, epigenetic dysregulation is an essential driver of leukemogenesis, and non-selective hypomethylating agents (HMAs) are the current backbone of non-intensive treatment. The first clinical trials that evaluated whether HMAs may improve immune checkpoint inhibitors' efficacy showed modest efficacy except for the anti-CD47 antibody that was substantially more efficient against AML when combined with azacitidine. Combining bispecific antibodies or cellular treatments with HMAs is subject to ongoing clinical investigation, and efficacy data are awaited shortly. More selective second-generation inhibitors targeting specific chromatin regulators have demonstrated promising preclinical activity against AML and are currently evaluated in clinical trials. These drugs that commonly cause leukemia cell differentiation potentially sensitize AML to immune-based treatments by co-regulating immune checkpoints, providing a pro-inflammatory environment, and inducing (neo)-antigen expression. Combining selective targeted epigenetic drugs with (cellular) immunotherapy is, therefore, a promising approach to avoid unintended effects and augment efficacy. Future studies will provide detailed information on how these compounds influence specific immune functions that may enable translation into clinical assessment.

Immune Evasion Through Human Leukocyte Antigen Implications and Its Impact on Targeted Therapy

HLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events

Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia

Human Leukocyte Antigen and Tumor Immunotherapy (Review)

The Importance of HHLA2 in Solid Tumors—A Review of the Literature

Mechanisms of Immunosuppressive Tumor Evasion: Focus on Acute Lymphoblastic Leukemia

The HLA-G immune checkpoint: a new immuno-stimulatory role for the α1-domain-deleted isoform

Harnessing the potential of HLA-G in cancer therapy: advances, challenges, and prospects

Role of HLA-G in Viral Infections

Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy

The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy?

HLA-G can be transfered via trogocytosis from leukemic cells to T cells in chronic lymphocytic leukemia

A membrane-associated MHC-I inhibitory axis for cancer immune evasion

HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)

Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation

Antigen presentation in cancer: insights into tumour immunogenicity and immune evasion

Genetic mechanisms of HLA-I loss and immune escape in diffuse large B cell lymphoma

Overcoming Immune Evasion in T Cell Therapy of Cancer: Lessons from Animal Models

Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy

Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies

Role of HLA-G in tumors and upon COVID-19 infection